^
Association details:
| Biomarker: | FGF19 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
Excerpt:
We showed that FGF19, when overexpressed, inhibited the effect of sorafenib on ROS generation and apoptosis in HCC.
DOI:
10.1186/s13046-016-0478-9
